1) Determina 662/2013, G.U. n.175 del 27/07/2013  
2) Determina G.U. 41/42 del 24/02/2007  
3) RCP Arixtra 5 mg  
4) RCP Arixtra 7.5 mg  
5) RCP Arixtra 10 mg 
6) Determina GU n.278 del 28-11-2017  
7) Mastroiacovo D et al. The safety of Fondaparinux sodium for the treatment of venous thromboembolism. Expert Opinion on Drug Safety 2016; 15:9, 1259-1265
8) Büller HR et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140(11):867-73
9) Büller HR et al. Subcutaneous Fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349(18):1695-702
10) Kearon C et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2) (Suppl):e419S–e494S
11) Konstantinides SV, Torbicki A, Agnelli G, et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033-80
12) Konstantinides S, Torbicki A. Management of venous thrombo-embolism: an update. European Heart Journal 2014; 35: 2855–2863 
13) RCP ARIXTRA 2.5 mg 
14) RCP ARIXTRA 1.5 mg